Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck & Co.
Biotech
M&A remains ‘top priority’ for pharmas in face of tariff threat
Big Pharmas aren’t letting the looming threat of potential tariffs divert them from their M&A strategies for the year—at least for the time being.
James Waldron
Apr 25, 2025 10:41am
Merck links up with Cyprumed in $493M oral peptide deal
Apr 15, 2025 1:11pm
A closer look at pharma's top R&D budgets
Apr 4, 2025 9:34am
Top 10 pharma R&D budgets in 2024
Mar 31, 2025 6:00am
Merck & Co. pens $200M upfront deal for Hengrui med
Mar 25, 2025 9:10am
Merck pens $300M-per-drug collab to find hidden tumor antigens
Feb 19, 2025 7:00am
